Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes - Radioactive & Nonradioactive

SHINE technology and progress toward U.S.-based molybdenum-99 production.

Katrina Pitas and Greg Piefer
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 165;
Katrina Pitas
1SHINE Medical Technologies, Monona, WI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Greg Piefer
1SHINE Medical Technologies, Monona, WI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

165

Objectives SHINE Medical will end medical isotope shortages using its LEU-fission-based production technology.

Methods A beam-target neutron generator drives fission in a subcritical, low-enriched uranium solution, producing medical isotopes such as molybdenum-99 (Mo-99), iodine-131, and xenon-133 in large quantities. The neutrons are produced as a result of deuterium-tritium fusion reactions in a gas target. Isotope production, separation, and purification are performed on a weekly basis. The process is cost-effective and creates less waste than conventional production methods, while eliminating the use of highly enriched uranium.

Results A facility housing eight irradiation units will be built in Janesville, WI and supply up to two-thirds of U.S. demand for Mo-99. SHINE expects to receive a construction permit from the Nuclear Regulatory Commission in late 2015 and to begin construction of its manufacturing facility in 2016.

Conclusions The SHINE technology produces high-specific activity Mo-99 that is compatible with the existing supply chain. Commercial sales of medical isotopes will begin in 2018.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 56, Issue supplement 3
May 1, 2015
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
SHINE technology and progress toward U.S.-based molybdenum-99 production.
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
SHINE technology and progress toward U.S.-based molybdenum-99 production.
Katrina Pitas, Greg Piefer
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 165;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
SHINE technology and progress toward U.S.-based molybdenum-99 production.
Katrina Pitas, Greg Piefer
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 165;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes - Radioactive & Nonradioactive

  • Design of calcium-sensing receptor targeted thera(g)nostic agents
  • Grade and IDH genotype prediction in glioma by a hybrid PET/MR with FET-PET and DSC-PWI
  • Syntheses of [11C]2- and [11C]3-trifluoromethyl-4-aminopyridine: potential PET radioligands for imaging demyelinating diseases
Show more Molecular Targeting Probes - Radioactive & Nonradioactive

Automation and Process Development

  • Metabolite profiling with HPLC-ICP-MS - a rapid and simple way to assess in vivo behavior of imaging probes.
  • Automated Processing of Cyclotron Produced 68Ga Using Hydroxamate Resin
  • Automated Clinical Product of [11C]Glutamine on Commercial Synthesis Modules
Show more Automation and Process Development

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire